Filing Flows › Connect Biopharma Holdings (CNTB) › Q2 2026
Connect Biopharma Holdings (CNTB) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 12, 2026
Connect Biopharma Holdings (CNTB) reported revenue of $2.8M for the second quarter 2026 (Q2 2026), up 58-fold from a year earlier and up 16-fold from the quarter before. Operating margin was -636.0%, net loss $17.3M (624.4% of revenue).
Connect Biopharma Holdings, Q2 2026: revenue $2.8M (58× year over year), operating margin -636.0%, net loss $17.3M, operating cash flow −$15.9M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.8M | 16× | 58× |
| Operating profit | −$17.6M | — | — |
| Net earnings | −$17.3M | — | — |
| Operating cash flow | −$15.9M | — | — |
What changed
Revenue was $2.8M in Q2 2026, up 5667% year over year and up 1538% from the previous quarter.
Operating costs exceeded revenue by $17.6M, an operating margin of -636.0%. Total costs grew 51% against revenue growth of 5667%. The fastest-growing cost line was Research & development (+85%). The quarter ended with a net loss of $17.3M, narrower than the previous quarter's $19.4M loss.
Operating cash flow was −$15.9M. Non-cash charges added back $161K of depreciation and amortization and $1.3M of share-based compensation.
Questions
What was Connect Biopharma Holdings' revenue in the second quarter 2026?
Connect Biopharma Holdings (CNTB) reported revenue of $2.8M for the second quarter 2026 (Q2 2026), up 58-fold from a year earlier and up 16-fold from the quarter before.
Was Connect Biopharma Holdings profitable in the second quarter 2026?
Operating loss was $17.6M (-636.0% of revenue) and net loss $17.3M.